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Abstract
Objective:
To assess treatment adherence to dipeptidyl peptidase-4 inhibitor vildagliptin compared with sulphonylureas
(SU) in Muslim patients with type 2 diabetes mellitus who were fasting during Ramadan in the UK.
Research design and methods:
This prospective, observational cohort study was conducted in four UK centres. Patients already taking
vildagliptin (50mg twice a day) or an SU as add-on therapy to metformin were followed up for 16 weeks.
They were asked to record all missed doses of anti-diabetes medications.
Results:
Of the 72 patients enrolled (vildagliptin, n¼ 30; SU, n¼ 41; not allocated to treatment, n¼ 1), 59 (81.9%)
completed the study (vildagliptin, n¼ 23; SU, n¼ 36), including one patient in the SU arm who completed
but failed to provide information on missed doses; all patients in the SU arm were taking gliclazide. In the
vildagliptin arm one patient (4.3%) missed a total of four doses while in the SU arm 10 patients (27.8%)
missed a total of 266 doses (mean [SD] number of doses missed per patient: 26.6 [16.5]). The mean (SD)
proportions of doses missed during fasting were 0.2% (0.9) and 10.4% (21.7) in the vildagliptin and SU
arms, respectively, with a significant mean between-group difference of 10.2% (95% CI: 19.3%,
1.1%; p¼ 0.0292). There were no patients in the vildagliptin arm who missed more than 20% of
OAD doses compared with 19.4% in the SU arm (p¼ 0.0358). Of the patients receiving an SU, 15
(42%) collectively reported 34 hypoglycaemic events (HEs) and one grade 2 HE; of these, fewer were
non-adherent (n¼ 6, 40%) than adherent (n¼ 9, 60%). No patients reported HEs in the vildagliptin arm.
Conclusion:
During Ramadan fasting, treatment with vildagliptin resulted in better treatment adherence compared with
SU in Muslim patients with type 2 diabetes mellitus. Study limitations are the sample size and the lack of diet
and exercise data.
Introduction
Fasting in patients with type 2 diabetes mellitus (T2DM) can be associated with
increased risk of both hypoglycaemia and hyperglycaemia. When using drugs
known to be associated with hypoglycaemia this risk is potentially higher
and glycaemic control deteriorates in some patients with diabetes who fast
during Ramadan1.
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In patients with T2DM, fasting increases the risk of
severe hypoglycaemia by 7.5 times and hospitalisation
due to hypoglycaemia by five times2. Hypoglycaemia is
an important limiting factor in managing glycaemic con-
trol in patients with T2DM and is also a significant barrier
to treatment adherence3. Apart from increased risk of
hypoglycaemia and hyperglycaemia, another challenge
during Ramadan fasting is compliance with treatment.
Studies have shown that patients change the intake of
drug doses and time without seeking appropriate health
care professional advice4. Furthermore, adherence to pre-
scribed oral anti-diabetes drugs (OADs) is poor in South
Asian patients5. Although a number of factors are attrib-
utable to poor treatment compliance during Ramadan, one
of the factors emerging is episodes of unreported hypogly-
caemia that could be responsible for patients omitting
their drugs in order to avoid the unpleasant side-effects
of hypoglycaemia and continue their fasting.
It has also been shown that patients may consider alter-
ing and adjusting the drug dose and timing appropriately
in order to avoid hypoglycaemia and enable completion
of fasting during Ramadan6. Considering the potential
medical complications and poor treatment adherence asso-
ciated with fasting, the choice of OAD therapy is therefore
particularly important.
Vildagliptin is a potent and selective dipeptidyl pepti-
dase-4 (DPP-4) inhibitor that improves glycaemic control
by increasing a- and -cell responsiveness to glucose.
It significantly reduces the risk of hypoglycaemia versus
sulphonylureas (SUs)7,8.
Results from the VECTOR (Vildagliptin Experience
Compared To gliclazide Observed during Ramadan)
study showed that, in Muslim patients with T2DM fasting
during Ramadan, vildagliptin as add-on to metformin
reduced glycated haemoglobin levels (HbA1c) without
hypoglycaemia in contrast to gliclazide add-on to metfor-
min9. The present report highlights the missed doses and
treatment adherence during Ramadan fasting from the
previously published VECTOR study.
Methods
Study design and patients
This was a post-authorisation, prospective, observational,
non-interventional study conducted at four centres in the
UK (N¼ 72). Patients were enrolled into two cohorts:
vildagliptin (50mg b.i.d.) plus metformin or SU plus met-
formin. Data were collected over a period of 16 weeks at
two data collection points, occurring 1–6 weeks prior to
commencement of fasting and 6 weeks after the fasting
period ended. Patients aged 18 years and diagnosed with
T2DM 12 months prior to fasting were enrolled, pro-
vided they had received vildagliptin or SU add-on to
metformin for 4 weeks prior to fasting, were planning
to fast for 10 days and had HbA1c 8.5% up to
1 month prior to fasting. Further details of the study
design and patient exclusion criteria are reported by
Hassanein et al.9.
Efficacy assessments
The main efficacy assessment was adherence to treatment
during Ramadan fasting. Treatment adherence was
assessed by expressing the number of doses missed (as rec-
orded in a patient-held diary) as a percentage of the total
number of doses prescribed. Subjects were also categorised
into whether they missed420% of doses or not.
Safety and tolerability
All adverse events (AEs) and serious AEs (SAEs) were
recorded and treated appropriately at the clinicians’
discretion. The suspected involvement of anti-diabetes
medication in any SAE, including grade 2 HEs (and any
recurrence), was also recorded. Routine liver function tests
were performed.
Statistical analysis
The difference in percentage doses missed (vildagliptin
minus SU) was tested by an unpaired t-test together with
a 95% confidence interval (CI) for the treatment differ-
ence. The proportion of patients missing or not missing
420% of OAD doses in each group was tested with Fisher’s
exact test.
Ethics
This observational study was conducted in accordance
with applicable local regulations and the ethical prin-
ciples of the Declaration of Helsinki (and any subse-
quent amendments). Patients provided written
informed consent before any assessment was performed.
The study protocol and informed consent forms were
reviewed and approved by the Multi-centre Research
Ethics Committee for Wales.
Results
Of the 72 patients enrolled, 59 (81.9%) completed the
study (vildagliptin, n¼ 23 [76.7%]; SU, n¼ 36 [87.8%])
including one patient in the SU arm who completed but
failed to provide information on missed doses. Patient
demographics and baseline characteristics are presented
in Table 1. Mean ages were comparable between groups
and most patients were aged565 years. There were more
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men (n¼ 33, 55.9%) than women (n¼ 26, 44.1%) and
nearly all patients were South Asians. Patients in the
vildagliptin group had longer T2DM duration than
the SU group and a slightly higher BMI and HbA1c.
Mean duration of fasting in both arms were comparable
(vildagliptin 25.0 6.6 days vs. SUs 25.4 5.8 days).
Discontinuations were due to loss to follow-up and
included patients who chose not to fast, did not attend
the second visit or did not take any medication. All
patients who completed the study were eligible for inclu-
sion in the per protocol and safety populations.
Efficacy outcomes
In the vildagliptin arm, one patient (4.3%) missed a total
of four doses; in the SU arm, 10 patients (27.8%) missed a
total of 266 doses (mean [SD] number of doses missed per
patient: 26.6 [16.5]). The mean (SD) proportion of doses
missed during fasting was 0.2% (0.9%) in the vildagliptin
arm and 10.4% (21.7%) in the SU arm, with a significant
between-group difference of 10.2% (95% CI: 19.3%,
1.1%); p¼ 0.0292. There were no patients in the vilda-
gliptin arm who missed more than 20% of OAD doses
compared with 19.4% in the SU arm (p¼ 0.0358)
(Figure 1). Of the patients receiving an SU, 15 (42%)
collectively reported 34 HEs and one grade 2 HE; of
these patients, fewer were non-adherent (n¼ 6, 40%)
than adherent (n¼ 9, 60%). Further details of the study
results are reported by Hassanein et al.9
Discussion
In this real-world observational study of Muslim patients
with T2DM fasting during Ramadan, a marked difference
in missed doses between the vildagliptin and SU treatment
groups was observed with only one patient (4.3%) in the
vildagliptin group missing at least one dose compared with
Table 1. Patient demographics and baseline characteristics.
Demographic/baseline variable Vildagliptin cohort n¼ 23 Sulphonylurea cohort n¼ 36 p-value#
Age (years) 58.3 13.06 57.3 11.03 0.6135
565 years, n (%) 17 (73.9) 28 (77.8) 0.7618
65 years, n (%) 6 (26.1) 8 (22.2)
Sex, n (%)
Male 12 (52.2) 21 (58.3) 0.7889
Female 11 (47.8) 15 (41.7)
Ethnicity, n (%)
South Asian 23 (100) 34 (94.4) 0.5161
Other 0 2 (5.6)
BMI (kg/m2) 29.6 5.0 28.5 3.9 0.3632
T2DM duration (years) 7.1 6.1 5.8 4.7 0.4553
HbA1c (%) 7.7 0.9 7.2 0.6 –
Any dose adjustments for Ramadan, n (%) 0 5 (13.9) –
Metformin adjusted 0 4 (11.1) –
Vildagliptin adjusted 0 – –
Gliclazide adjusted – 3 (8.3) –
Median total dose before fasting, mg/day
Metformin 2000 2000 –
Vildagliptin 100 – –
Gliclazide – 80* –
Median total dose after Ramadan adjustments, mg/day
Metformin 2000 2000 –
Vildagliptin 100 – –
Gliclazide – 80* –
Data are shown mean SD, unless otherwise stated.
#p-value Wilcoxon two-sample test for continuous variables, Fisher’s exact test for categorical variables.
*Different formulations were used for gliclazide therefore the following conversion factor was used: 80 mg standard formulation 30 mg
modified release formulation.
0
*
19.4
0
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Figure 1. Proportion of patients missing420% of drug doses during
Ramadan fasting. *p¼ 0.0358 vs. SU.
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10 patients (27.8%) in the SU group. This equates to four
missed doses in the vildagliptin arm compared with 266 in
the SU arm. Better treatment adherence with vildagliptin
was most likely due to better tolerability with patients
having less fear of hypoglycaemia, which is a significant
barrier to adherence and can adversely affect quality of life
by causing distress and serious morbidity3. Furthermore,
better adherence was found to be associated with improved
glycaemic control in the vildagliptin arm9.
Patients’ self-management and adherence to drugs are
key to good glycaemic control. Several studies have shown
that patients arbitrarily change the intake of drug doses
and time without seeking medical advice5. It has also
been noted that adherence to prescribed OADs in certain
patient populations, such as South Asian patients, is poor,
that they give less importance to controlling their diabetes,
and they may be less anxious than white patients about
adhering to their treatments4. For example, Pakistani
and Indian patients may adjust their OADs according to
symptoms. It is increasingly recognised that if adherence
is to be improved, patients’ perspectives must be better
understood4.
The results from the present study show that with vil-
dagliptin there were no HEs reported as compared with
nearly half of the patients in the SU group experiencing
HEs. The difference in the proportion of patients experi-
encing HEs in the present study (41.7%) was in line with
previous findings in favour of vildagliptin from a UK retro-
spective audit in T2DM patients fasting during Ramadan
(53.8%)10. Furthermore, results from a recent observa-
tional study that compared sitagliptin with SU treatment
also showed a low risk of hypoglycaemia with sitagliptin
compared with the SU arm in patients with T2DM fasting
during Ramadan11. Improvement in HbA1c was found to
be significant with vildagliptin than SU despite the short
study duration9. This may be due to better adherence, less
defensive eating, and/or higher baseline HbA1c in patients
in this cohort (7.7% vs. 7.2%) than the SU group. This
study had some limitations, including the small sample size
and a lack of diet, eating pattern, and exercise data.
As Muslim patients with T2DMmay still choose to fast
during Ramadan, it is important that fasting is made as safe
as possible in this patient population. Use of DPP-4 inhibi-
tors in fasting patients has been shown to improve glucose
control with low risk of hypoglycaemia as well as better
treatment adherence9. For physicians, this translates to less
time and fewer resources spent treating complications of
hypoglycaemia and uncontrolled blood glucose, a safer
option for achieving glycaemic targets, and, ultimately, a
reduction in cost.
Our findings are an important addition to the existing
evidence that helps physicians choose between classes of
OAD therapy. If our study is representative of the 260,000
UK Muslims with T2DM believed to fast during Ramadan
each year, many of whomwould be on a similar therapeutic
combination, this will have significant public health and
clinical implications.
Conclusion
In this study, during Ramadan fasting, almost all Muslim
patients with T2DM receiving vildagliptin add-on to met-
formin adhered to treatment and none reported HEs.
In contrast, nearly half the studied patients receiving an
SU add-on to metformin experienced HEs and almost one-
third missed doses. Of note, the majority of patients who
experienced HEs were adherent to their therapy. Our find-
ings highlight the importance of choosing an OAD ther-
apy that matches the patient’s lifestyle and suggest that
vildagliptin is a suitable treatment option in Muslim
patients with T2DM who fast during Ramadan.
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